Connection

MARGARET SPITZ to Mutagens

This is a "connection" page, showing publications MARGARET SPITZ has written about Mutagens.
Connection Strength

3.151
  1. Interplay between mutagen sensitivity and epidemiological factors in modulatinglung cancer risk. Int J Cancer. 2007 Jun 15; 120(12):2687-95.
    View in: PubMed
    Score: 0.269
  2. Mutagen sensitivity: a genetic predisposition factor for cancer. Cancer Res. 2007 Apr 15; 67(8):3493-5.
    View in: PubMed
    Score: 0.265
  3. Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. Clin Cancer Res. 2006 Dec 01; 12(23):7194-201.
    View in: PubMed
    Score: 0.259
  4. Assessment of insulin-like growth factors and mutagen sensitivity as predictors of lung cancer risk. Methods Mol Med. 2003; 75:279-87.
    View in: PubMed
    Score: 0.197
  5. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. J Natl Cancer Inst. 2000 May 03; 92(9):737-43.
    View in: PubMed
    Score: 0.164
  6. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. Growth Horm IGF Res. 2000 Apr; 10 Suppl A:S26-7.
    View in: PubMed
    Score: 0.163
  7. Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J Natl Cancer Inst. 1998 Sep 16; 90(18):1393-9.
    View in: PubMed
    Score: 0.146
  8. Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract. J Natl Cancer Inst. 1998 Feb 04; 90(3):243-5.
    View in: PubMed
    Score: 0.140
  9. Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis. 1997 May; 18(5):967-73.
    View in: PubMed
    Score: 0.133
  10. Mutagen sensitivity exhibits a dose-response relationship in case-control studies. Cancer Epidemiol Biomarkers Prev. 1996 Jul; 5(7):577-8.
    View in: PubMed
    Score: 0.126
  11. Mutagen sensitivity as a marker of cancer susceptibility. J Cell Biochem Suppl. 1996; 25:80-4.
    View in: PubMed
    Score: 0.121
  12. Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev. 1995 Mar; 4(2):99-103.
    View in: PubMed
    Score: 0.115
  13. Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst. 1994 Nov 16; 86(22):1681-4.
    View in: PubMed
    Score: 0.112
  14. Mutagen sensitivity as a marker of cancer risk. Cancer Detect Prev. 1994; 18(4):299-303.
    View in: PubMed
    Score: 0.106
  15. Mutagen sensitivity in upper aerodigestive tract cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 1993 Jul-Aug; 2(4):329-33.
    View in: PubMed
    Score: 0.102
  16. Ethyl alcohol as a cocarcinogen with special reference to the aerodigestive tract: a cytogenetic study. Anticancer Res. 1991 May-Jun; 11(3):1097-101.
    View in: PubMed
    Score: 0.088
  17. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis. Cancer Epidemiol Biomarkers Prev. 2006 Oct; 15(10):1935-40.
    View in: PubMed
    Score: 0.064
  18. Mutagen sensitivity has high heritability: evidence from a twin study. Cancer Res. 2006 Jun 15; 66(12):5993-6.
    View in: PubMed
    Score: 0.063
  19. Benzo[a]pyrene diol epoxide-induced 9p21 aberrations associated with genetic predisposition to bladder cancer. Genes Chromosomes Cancer. 2004 Dec; 41(4):330-8.
    View in: PubMed
    Score: 0.056
  20. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev. 2003 Aug; 12(8):689-98.
    View in: PubMed
    Score: 0.051
  21. Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. Cancer Res. 2002 May 15; 62(10):2813-8.
    View in: PubMed
    Score: 0.047
  22. Family history of cancer, mutagen sensitivity, and increased risk of head and neck cancer. Cancer Lett. 1999 Nov 01; 146(1):93-101.
    View in: PubMed
    Score: 0.040
  23. Three measures of mutagen sensitivity in a cancer-free population. Cancer Genet Cytogenet. 1999 Apr; 110(1):65-9.
    View in: PubMed
    Score: 0.038
  24. Reduced DNA repair capacity in lung cancer patients. Cancer Res. 1996 Sep 15; 56(18):4103-7.
    View in: PubMed
    Score: 0.032
  25. A statistical analysis of the reliability and classification error in application of the mutagen sensitivity assay. Cancer Epidemiol Biomarkers Prev. 1996 Mar; 5(3):191-7.
    View in: PubMed
    Score: 0.031
  26. DNA repair capacity correlates with mutagen sensitivity in lymphoblastoid cell lines. Cancer Epidemiol Biomarkers Prev. 1996 Mar; 5(3):199-204.
    View in: PubMed
    Score: 0.031
  27. Lung cancer, smoking patterns, and mutagen sensitivity in Mexican-Americans. J Natl Cancer Inst Monogr. 1995; (18):29-33.
    View in: PubMed
    Score: 0.028
  28. Genetic susceptibility to cancer. Cancer. 1993 Aug 01; 72(3 Suppl):991-5.
    View in: PubMed
    Score: 0.026
  29. Association between family history of cancer and mutagen sensitivity in upper aerodigestive tract cancer patients. Cancer Epidemiol Biomarkers Prev. 1993 Mar-Apr; 2(2):103-6.
    View in: PubMed
    Score: 0.025
  30. Mutagen sensitivity in patients with head and neck cancers: a biologic marker for risk of multiple primary malignancies. J Natl Cancer Inst. 1990 Nov 21; 82(22):1773-5.
    View in: PubMed
    Score: 0.021
  31. Human sensitivity to PhIP: a novel marker for prostate cancer risk. Mutat Res. 2006 Oct 10; 601(1-2):1-10.
    View in: PubMed
    Score: 0.016
  32. Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer. Cancer. 2006 Jun 15; 106(12):2636-44.
    View in: PubMed
    Score: 0.016
  33. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res. 2005 Apr 15; 11(8):2894-8.
    View in: PubMed
    Score: 0.014
  34. Genetic instability of specific chromosomes associated with a family history of cancer. Cancer Genet Cytogenet. 2002 Jul 01; 136(1):73-7.
    View in: PubMed
    Score: 0.012
  35. Comparative efficacy as antioxidants between ascorbic acid and epigallocatechin gallate on cells of two human lymphoblastoid lines. Cancer Genet Cytogenet. 2001 Jan 15; 124(2):169-71.
    View in: PubMed
    Score: 0.011
  36. Mutagen sensitivity as a susceptibility marker for human hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 1998 Jul; 7(7):567-70.
    View in: PubMed
    Score: 0.009
  37. Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst. 1996 Apr 17; 88(8):530-5.
    View in: PubMed
    Score: 0.008
  38. p53 mutations in nonmelanoma skin cancer of the head and neck: molecular evidence for field cancerization. Cancer Res. 1995 Aug 15; 55(16):3604-9.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.